Search Results (70)
Click the Why column to see why an item matched the search.
| Match | Type | Why |
|---|
| Gaedigk, Andrea | Person |
Why?
|
| Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. | Academic Article |
Why?
|
| CYP2C19-Guided Escitalopram and Sertraline Dosing in Pediatric Patients: A Pharmacokinetic Modeling Study. | Academic Article |
Why?
|
| PharmVar GeneFocus: CYP2C19. | Academic Article |
Why?
|
| Cytochrome P-450 CYP2C19 | Concept |
Why?
|
| Cytochrome P-450 CYP2C19 Inducers | Concept |
Why?
|
| Cytochrome P-450 CYP2C19 Inhibitors | Concept |
Why?
|
| A fresh look at proton pump inhibitor (PPI)-associated adverse events through a CYP2C19 pharmacogenetic lens. | Academic Article |
Why?
|
| Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update. | Academic Article |
Why?
|
| Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. | Academic Article |
Why?
|
| Letter to the Editor: The Impact of Adherence and CYP2C19 Phenotype on Escitalopram Exposure in Adolescents. | Academic Article |
Why?
|
| Utility of the 13 C-pantoprazole breath test as a CYP2C19 phenotyping probe for children. | Academic Article |
Why?
|
| Impact of CYP2C:TG Haplotype on CYP2C19 Substrates Clearance In Vivo, Protein Content, and In Vitro Activity. | Academic Article |
Why?
|
| Prospective CYP2C19-Guided Voriconazole Prophylaxis in Patients With Neutropenic Acute Myeloid Leukemia Reduces the Incidence of Subtherapeutic Antifungal Plasma Concentrations. | Academic Article |
Why?
|
| CYP2C19 genotyping and associated mephenytoin hydroxylation polymorphism in a Canadian Inuit population. | Academic Article |
Why?
|